| 摘要 |
FIELD: medicine.SUBSTANCE: determining an initial level of total lymphocyte count ?2500/mcl and CD16+56+ lymphocyte ?440/mcl count is considered a positive prognostic factor of a virologic reponse to the interferon therapy. An initial level of total lymphocyte count ?2000/mcl and CD 16+56+ lymphocyte count ?440/mcl is considered a negative prognostic factor of a virologic reponse. The initial level of total lymphocyte count within the range of 2000-2500 is considered an indication of a follow-up care with underlying treatment. Then, 12 weeks after the interferon therapy, total lymphocyte count, CD3+ lymphocyte count, CD3+CD4+ lymphocyte count and CD16+56+ lymphocyte count in 1 mcl are determined. If observing an increase in total lymphocyte count ?2500/mcl, CD3+ lymphocyte count ?1900/mcl, CD3+CD4+lymphocyte count ?1000/mcl and CD16+56+ lymphocyte count >440/mcl in relation to the initial level, a positive prognosis of the clinical effectiveness of the interferon therapy is concluded.EFFECT: using the given method enables predicting the clinical effectiveness of the interferon therapy before the beginning thereof and ensuring an individual approach to prescribing the therapy in chronic hepatitis C.2 ex |
